Targeting both PTGDR-1 and PTGDR-2 seems a valuable therapeutic approach to prevent flares in patients with SLE and in other diseases involving basophil, PGD2, and CXCL12 such as allergic diseases, chronic urticaria, asthma, inflammatory bowel diseases, and other chronic inflammatory disorders. Here, CXCL12 is linked to inflammatory bowel disease.